These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38776433)

  • 1. Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma.
    Ludwig H; Munshi NC; Terpos E; Schweitzer I; Raje N; Moreau P; Nooka A
    Blood Adv; 2024 Sep; 8(18):4979-4982. PubMed ID: 38776433
    [No Abstract]   [Full Text] [Related]  

  • 2. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
    Alqazaqi R; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Tricot G; van Rhee F; Al Hadidi S
    JAMA Netw Open; 2022 Aug; 5(8):e2228877. PubMed ID: 36018590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
    Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
    Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
    Kazandjian D; Kowalski A; Landgren O
    Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific Antibodies in Multiple Myeloma: Present and Future.
    Lancman G; Sastow DL; Cho HJ; Jagannath S; Madduri D; Parekh SS; Richard S; Richter J; Sanchez L; Chari A
    Blood Cancer Discov; 2021 Sep; 2(5):423-433. PubMed ID: 34661161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Antibodies for the Treatment of Multiple Myeloma.
    Goldsmith SR; Streeter S; Covut F
    Curr Hematol Malig Rep; 2022 Dec; 17(6):286-297. PubMed ID: 36029366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth.
    Wu L; Huang Y; Sienkiewicz J; Sun J; Guiang L; Li F; Yang L; Golubovskaya V
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
    Reynolds G; Cliff ERS; Mohyuddin GR; Popat R; Midha S; Liet Hing MN; Harrison SJ; Kesselheim AS; Teh BW
    Blood Adv; 2023 Oct; 7(19):5898-5903. PubMed ID: 37467036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and emerging pharmacotherapies for the management of multiple myeloma.
    Moore DC; Oxencis CJ; Shank BR
    Am J Health Syst Pharm; 2022 Jul; 79(14):1137-1145. PubMed ID: 35333922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies in multiple myeloma treatment: A journey in progress.
    Cho SF; Yeh TJ; Anderson KC; Tai YT
    Front Oncol; 2022; 12():1032775. PubMed ID: 36330495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
    Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ
    Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific Antibodies in the Treatment of Multiple Myeloma.
    Zhou X; Xiao X; Kortuem KM; Einsele H
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
    Moreau P; Touzeau C
    Blood; 2022 Jun; 139(26):3681-3687. PubMed ID: 35404996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
    Lancman G; Parsa K; Kotlarz K; Avery L; Lurie A; Lieberman-Cribbin A; Cho HJ; Parekh SS; Richard S; Richter J; Rodriguez C; Rossi A; Sanchez LJ; Thibaud S; Jagannath S; Chari A
    Blood Cancer Discov; 2023 Nov; 4(6):440-451. PubMed ID: 37769148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
    Parrondo RD; Ailawadhi S; Cerchione C
    Front Oncol; 2024; 14():1394048. PubMed ID: 38660139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma.
    Castaneda-Puglianini O; Chavez JC
    Drugs Context; 2021; 10():. PubMed ID: 34603459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.